Neumora Therapeutics Inc. Common Stock (NMRA) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Neumora Therapeutics, Inc.

NASDAQ | NMRA

0.65

USD

+0.0168 (+2.67%)

AT CLOSE (AS OF Apr 17, 2025)

$105M

MARKET CAP

P/E Ratio

-1.53

EPS

$17

52 Week High

$0.62

52 Week Low

LIFE SCIENCES

Sector

NMRA Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

NMRA Technicals

Tags:

NMRA Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	-
Total Revenue	$0
Cost Of Revenue	-
Costof Goods And Services Sold	-
Operating Income	-$263M
Selling General And Administrative	$63M
Research And Development	$201M
Operating Expenses	$263M
Investment Income Net	-
Net Interest Income	$20M
Interest Income	$20M
Interest Expense	-
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	-
Income Before Tax	-$244M
Income Tax Expense	$178K
Interest And Debt Expense	-
Net Income From Continuing Operations	-$244M
Comprehensive Income Net Of Tax	-
Ebit	-
Ebitda	-$263M
Net Income	-$244M

Revenue & Profitability

Earnings Performance

NMRA Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2024)

Field	Value (USD)
Total Assets	$317M
Total Current Assets	$314M
Cash And Cash Equivalents At Carrying Value	$142M
Cash And Short Term Investments	$142M
Inventory	-
Current Net Receivables	-
Total Non Current Assets	$2.9M
Property Plant Equipment	-
Accumulated Depreciation Amortization Ppe	-
Intangible Assets	-
Intangible Assets Excluding Goodwill	-
Goodwill	-
Investments	-
Long Term Investments	$0
Short Term Investments	$165M
Other Current Assets	$6.5M
Other Non Current Assets	-
Total Liabilities	$30M
Total Current Liabilities	$30M
Current Accounts Payable	-
Deferred Revenue	-
Current Debt	-
Short Term Debt	$1.9M
Total Non Current Liabilities	$22K
Capital Lease Obligations	$1.9M
Long Term Debt	-
Current Long Term Debt	-
Long Term Debt Noncurrent	-
Short Long Term Debt Total	$1.9M
Other Current Liabilities	$25M
Other Non Current Liabilities	$22K
Total Shareholder Equity	$287M
Treasury Stock	-
Retained Earnings	-$947M
Common Stock	$16K
Common Stock Shares Outstanding	$159M

yearly Cash Flow (As of Dec 31, 2024)

Field	Value (USD)
Operating Cashflow	-$183M
Payments For Operating Activities	-
Proceeds From Operating Activities	-
Change In Operating Liabilities	-
Change In Operating Assets	-
Depreciation Depletion And Amortization	$631K
Capital Expenditures	$0
Change In Receivables	-
Change In Inventory	-
Profit Loss	-
Cashflow From Investment	-
Cashflow From Financing	$22M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	-
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	$0
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	-$244M

yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	-
Total Revenue	$0
Cost Of Revenue	-
Costof Goods And Services Sold	-
Operating Income	-$263M
Selling General And Administrative	$63M
Research And Development	$201M
Operating Expenses	$263M
Investment Income Net	-
Net Interest Income	$20M
Interest Income	$20M
Interest Expense	-
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	-
Income Before Tax	-$244M
Income Tax Expense	$178K
Interest And Debt Expense	-
Net Income From Continuing Operations	-$244M
Comprehensive Income Net Of Tax	-
Ebit	-
Ebitda	-$263M
Net Income	-$244M

NMRA News

NMRA Profile

Neumora Therapeutics, Inc. Profile

Sector: LIFE SCIENCES

Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company is headquartered in Watertown, Massachusetts.

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.00	9.68%	-	409,386,220
STSS	$0.03	20.75%	$522.68K	391,799,240
NVDA	$101.49	-2.87%	$2.48T	292,517,465
HTZ	$8.24	44.31%	$2.54B	266,908,117
FMTO	$0.02	-35.81%	$2.41M	198,396,141

Symbol	Price	Change %	Market Cap	Volume
LLY	$839.96	14.30%	$754.27B	10,853,385
PG	$170.63	2.55%	$400.10B	7,227,061
JNJ	$157.47	2.31%	$379.48B	10,981,067
ABBV	$172.99	0.76%	$306.02B	8,998,056
NVO	$58.08	-7.63%	$282.79B	32,220,629

Symbol	Price	Change %	Market Cap	Volume
MSGM	$2.75	145.54%	$8.75M	36,058,545
SXTC	$2.16	118.42%	$29.73M	51,508,885
ADGM	$1.78	92.81%	$54.65M	114,733,769
PNBK	$3.28	73.55%	$13.04M	1,511,087
RTC	$0.37	72.09%	$10.86M	187,018,434

Symbol	Price	Change %	Market Cap	Volume
JEWL	$0.00	-90.83%	$2.78M	470,134
LXEH	$6.84	-70.25%	$26.82M	1,373,607
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
MMV	$0.48	-51.02%	$11.90M	1,568,644

Quick Links

NMRA $0.65 (+2.67%) Quote details